Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia a

PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 29, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

May 1, 2033

Conditions
Hemophilia a
Interventions
BIOLOGICAL

Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII

"Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with a history of FVIII inhibitors (≥0.6BU).~The infusion volume of transduced cells will not exceed 20 ml/kg body weight."

Trial Locations (1)

53226

RECRUITING

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER